参考文献/References:
[1] Schwartz PJ,Stramba-Badiale M,Crotti L,et al. Prevalence of the congenital long-QT syndrome[J]. Circulation,2009,120(18):1761-1767.
[2] 李翠兰,高元丰,刘文玲. 长QT综合征分子遗传学进展及国人基因变异汇总[J]. 临床心血管病杂志,2023;39(3):176-181.
[3] Gibbs C,Thalamus J,Tveten K,et al. Genetic and phenotypic characterization of community hospital patients with QT prolongation[J]. J Am Heart Assoc,2018;7(16):e009706.
[4] Wallace E,Howard L,Liu M,et al. Long QT syndrome:genetics and future perspective[J]. Pediatr Cardiol,2019,40(7):1419-1430.
[5] Wilde AAM,Amin A. Channelopathies,genetic testing and risk stratification[J]. Int J Cardiol,2017,237:53-55.
[6] Baruteau AE,Kyndt F,Behr ER,et al. SCN5A mutations in 442 neonates and children:genotype-phenotype correlation and identification of higher-risk subgroups[J]. Eur Heart J,2018,39(31):2879-2887.
[7] Zhang L,Timothy KW,Vincent GM,et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome:ECG findings identify genotypes[J]. Circulation,2000,102(23):2849-2855.
[8] Li G,Zhang L. The role of mexiletine in the management of long QT syndrome[J]. J Electrocardiol,2018,51(6):1061-1065.
[9] Zareba W,Moss AJ,Locati EH,et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype[J]. J Am Coll Cardiol,2003,42(1):103-109.
[10] Zimmer T,Surber R. SCN5A channelopathies--an update on mutations and mechanisms[J]. Prog Biophys Mol Biol,2008,98(2-3):120-136.
[11] Schwartz PJ,Moss AJ,Vincent GM,et al. Diagnostic criteria for the long QT syndrome. An update. Circulation,1993;88(2):782-784.
[12] Kapplinger JD,Giudicessi JR,Ye D,et al. Enhanced classification of brugada syndrome-associated and long-QT syndrome-associated genetic variants in the SCN5A-encoded Na v1.5 cardiac sodium channel[J]. Circ Cardiovasc Genet,2015,8(4):582-595.
[13] Shimizu W,Makimoto H,Yamagata K,et al. Association of genetic and clinical aspects of congenital long QT syndrome with life-threatening arrhythmias in Japanese patients[J]. JAMA Cardiol,2019,4(3):246-254.
[14] Yokoyama Y,Aiba T,Ueda N,et al. Subcutaneous and transvenous implantable cardioverter defibrillator in high-risk long-QT syndrome type 3 associated with Val411Met mutation in SCN5A[J]. J Cardiol Cases,2020,22(5):238-241.
[15] Wilde AAM,Amin AS. Clinical spectrum of SCN5A mutations:long QT syndrome,Brugada syndrome,and cardiomyopathy[J]. JACC Clin Electrophysiol,2018,4(5):569-579.
[16] Blich M,Khoury A,Suleiman M,et al. Specific therapy based on the genotype in a malignant form of long QT3,carrying the V411M mutation[J]. Int Heart J,2019,60(4):979-982.
[17] Pérez-Riera AR,Barbosa-Barros R,Daminello Raimundo R,et al. The congenital long QT syndrome Type 3:An update[J]. Indian Pacing Electrophysiol J,2018,18(1):25-35.
[18] El-Sherif N,Turitto G,Boutjdir M. Congenital long QT syndrome and torsade de pointes[J]. Ann Noninvasive Electrocardiol,2017,22(6):e12481.
[19] Ruan Y,Liu N,Bloise R,et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients[J]. Circulation,2007,116(10):1137-1144.
[20] Liu J,Bayer JD,Aschar-Sobbi R,et al. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome:implications for Na+ channel blocking pharmacotherapy for de novo conduction disease[J]. PLoS One,2018,13(5):e0197273.
[21] Zareba W. Genotype-specific ECG patterns in long QT syndrome[J]. J Electrocardiol,2006,39(4 Suppl):S101-S106.
[22] Schulze-Bahr E,Fenge H,Etzrodt D,et al. Long QT syndrome and life threatening arrhythmia in a newborn:molecular diagnosis and treatment response[J]. Heart,2004,90(1):13-16.
[23] Kehl HG,Haverkamp W,Rellensmann G,et al. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia:successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3[J]. Circulation,2004,109(18):e205-206.
[24] Ruan Y,Denegri M,Liu N,et al. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3[J]. Circ Res,2010,106(8):1374-1383.
[25] Zhu W,Mazzanti A,Voelker TL,et al. Predicting patient response to the antiarrhythmic mexiletine based on genetic variation[J]. Circ Res,2019,124(4):539-552.
[26] Wang DW,Yazawa K,George AL Jr,et al. Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome[J]. Proc Natl Acad Sci U S A,1996,93(23):13200-13205.
[27] Nieto-Mar ín P,Jiménez-Jáimez J,Tinaquero D,et al. Digenic heterozigosity in SCN5A and CACNA1C explains the variable expressivity of the long QT phenotype in a Spanish family[J]. Rev Esp Cardiol (Engl Ed),2019,72(4):324-332.
[28] Malan D,Zhang M,Stallmeyer B,et al. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction[J]. Basic Res Cardiol,2016,111(2):14.
[29] Murphy LL,Moon-Grady AJ,Cuneo BF,et al. Developmentally regulated SCN5A splice variant potentiates dysfunction of a novel mutation associated with severe fetal arrhythmia[J]. Heart Rhythm,2012,9(4):590-597.
[30] Moore JP,Gallotti RG,Shannon KM,et al. Genotype predicts outcomes in fetuses and neonates with severe congenital long QT syndrome[J]. JACC Clin Electrophysiol,2020,6(12):1561-1570.
[31] Horigome H,Nagashima M,Sumitomo N,et al. Clinical characteristics and genetic background of congenital long-QT syndrome diagnosed in fetal,neonatal,and infantile life:a nationwide questionnaire survey in Japan[J]. Circ Arrhythm Electrophysiol,2010,3(1):10-17.
[32] Schwartz PJ,Spazzolini C,Crotti L. All LQT3 patients need an ICD:true or false?[J]. Heart Rhythm,2009,6(1):113-120.